Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904293 · ClinicalTrials.gov registry record · NA
Genotype-Guided Warfarin Therapy Trial
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 109
- Enrollment target
NCT00904293: Completed NA study, sponsored by University of North Carolina, Chapel Hill.
NCT00904293 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 109 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904293, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 109 participants
- Enrollment target
Study Summary
The purpose of the investigators' study is to determine the clinical utility of a warfarin-dosing algorithm that incorporates genetic information (VKORC1 and CYP2C9 alleles) for adult patients initiating warfarin therapy.
Interventions
- OTHER Genotype-guided dose determination
- OTHER Non-genotype guided warfarin dosing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-01 |
| Phase | NA |
What the finished NCT00904293 record still lists
NCT00904293 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Genotype-guided dose determination is the first listed.
NCT00904293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00904293 about?
NCT00904293 is a clinical study titled "Genotype-Guided Warfarin Therapy Trial". The purpose of the investigators' study is to determine the clinical utility of a warfarin-dosing algorithm that incorporates genetic information (VKORC1 and CYP2C9 alleles) for adult patients initiating warfarin therapy.
What is the current status of trial NCT00904293?
This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2008-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00904293?
The interventions under investigation include: Genotype-guided dose determination (OTHER), Non-genotype guided warfarin dosing (OTHER).
Who is sponsoring clinical trial NCT00904293?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00904293's enrollment target sits among peer trials
109 825th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia